What question did this study set out to answer?

This research aims to evaluate the safety and efficacy of dexamethasone for managing cytokine release syndrome (CRS) in patients receiving talquetamab for relapsed/refractory multiple myeloma.

December 8, 2025BloodOpen Access

Dexamethasone for management of cytokine release syndrome (CRS) associated with talquetamab in patients with Relapsed/Refractory multiple myeloma

View Full Paper

Ask AI

Bookmark

Authors

KJKelley JulianUniversity of Utah JSJordan SnyderThe University of Kansas Cancer Center MRMikhaila RiceCleveland Clinic

Discussion

Member takes

Implication

Multicenter study demonstrates efficacy of dexamethasone for cytokine release syndrome in relapsed/refractory myeloma, suggesting clinical feasibility over tocilizumab.

Key Points

This research aims to evaluate the safety and efficacy of dexamethasone for managing cytokine release syndrome (CRS) in patients receiving talquetamab for relapsed/refractory multiple myeloma.
Conducted a multicenter retrospective study across seven academic medical centers.
Analyzed data from 211 patients with relapsed/refractory multiple myeloma receiving talquetamab.
Graded CRS and ICANS per ASTCT criteria, comparing outcomes based on intervention sequence (dexamethasone vs tocilizumab).
CRS occurred in 129 patients (61%) with varying severity grades.
Dexamethasone was first administered to 46 patients, resulting in a 72% occurrence of grade 1 CRS.
Overall response rate was 77%, with no significant difference in efficacy outcomes between dexamethasone and tocilizumab.

Cite This Study

Julian et al. (2025) studied this question.

synapsesocial.com/papers/69362f7d4fa91c937236e4cb https://doi.org/10.1182/blood-2025-720

View Full Paper

Ask AI

Bookmark

Implication

Multicenter study demonstrates efficacy of dexamethasone for cytokine release syndrome in relapsed/refractory myeloma, suggesting clinical feasibility over tocilizumab.

Dexamethasone for management of cytokine release syndrome (CRS) associated with talquetamab in patients with Relapsed/Refractory multiple myeloma

Discussion

Member takes

Implication

Key Points

Cite This Study

Dexamethasone for management of cytokine release syndrome (CRS) associated with talquetamab in patients with Relapsed/Refractory multiple myeloma

Discussion

Member takes

Implication

Key Points

Cite This Study

Also Consider

Also Consider